Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
RCT001
/
Roca Therap
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
RCT001
/
Roca Therap
Journal:
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
(Pubmed Central) - Mar 24, 2024
RCT001, by inhibiting CXCR2 through its unique mechanism, effectively suppresses ccRCC cell proliferation, angiogenesis, and M2 macrophage polarization. This optimization potentiates the efficacy of immunotherapy and holds promise for significantly improving the survival prospects of metastatic ccRCC patients.